Background and Objectives: The aims of this study were the establishment of a WHO International standard for HCV RNA for nucleic acid amplification technology (NAT) assays and the determination of the HCV RNA content of the candidate standard. Materials and Methods: Twenty–two laboratories evaluated three candidate materials (two lyophilised, AA and BB, which were derived from the same source and one a liquid preparation, CC). All samples were HCV genotype 1 with a concentration of approximately 105 genome equivalents/ml. The methods used included the Roche Amplicor assay (version 1), Chiron Quantiplex (bDNA) assay, Organon Teknika NASBA assay, Transcription Mediated assay and various in–house assays, using single or nested primers. Results: There was reasonable agreement between the overall mean NAT detectable units/ml obtained by the different assays except for some of the in–house assays using single primers which gave substantially lower estimates. These titres were 5.0 log10 for samples AA and BB and 4.6 log10 for sample CC. Conclusions: Sample AA was accepted as the candidate standard and assigned a titre of 105 international units (IU)/ml. The International Standard consists of a batch of vials each containing 50,000 IU/vial. Preliminary studies indicated that the material is stable at +4°C and +20°C for up to 200 days.

1.
Introduction of Gene Amplification Techniques (GAT) for Detection of Hepatitis C Virus in Plasma Pools: Addentum to Notes for Guidelines on Plasma Derived Products 1997; CPMP/BWP/390/97.
2.
Zaaijer H, Cuypers H, Reesink H, Winkel I, Gerken G, Lelie P: Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341:722–724.
3.
Saldanha J, Minor P: Collaborative study to assess the suitability of an HCV RNA reference sample for detection of an HCV RNA in plasma pools by PCR. Vox Sang 1996;70:148– 151.
4.
Damen M, Zaaijer H, Reesink H, Schaaberg W, Gerlich W, Niesters H, Lelie P: International collaborative study on the second Eurohep HCV–RNA reference panel. J Virol Methods 1996;58:175–185.
5.
Collet D: Modelling Binary Data. London, Chapman & Hall, 1991.
6.
Francis B, Green M, Payne C (eds): The GLIM System, Release 4 Manual Oxford Science Publications. Oxford, Clarendon Press, 1993.
7.
Saldanha J, Minor P: A sensitive PCR method for detecting HCV RNA in plasma pools, blood products and single donations. J Med Virol 1994;43:72–76.
8.
Rogers PM, Saldanha J, Allain JP: Report of EPFA/NIBSC Workshop Nucleic Acid Amplification Tests (NAT) for the Detection of Blood–Borne Viruses, Amsterdam, Oct 1996. Vox Sang 1997;72:199–206.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.